Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zoetis

Zoetis (ZTS): Analyzing Earnings for Potential Gains

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

StockNews.com

Zoetis Stock Rising — A Good Addition For Your Portfolio?

Zoetis stock shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Kevin O’Leary’s net worth: 'Shark Tank' investments, businesses, & more

"Mr. Wonderful" Kevin O'Leary is the toughest sell on 'Shark Tank'–but how did he make his fortune, and what is he worth now?

The Street

Management consultants can make great CEOs—but they have to get their hands dirty first

Some 47 Fortune 500 CEOs have spent time as management consultants but first took more junior roles.

Fortune

Market Rally On The Ropes, AI Stocks Tumble: Weekly Review

The market rally suffered more damage as the Nasdaq undercut key support and many leading AI stocks sold off hard.

Investors Business Daily

Drugmaker Zoetis Stock Shows Rising Relative Strength

A Relative Strength Rating upgrade for Zoetis shows improving technical performance.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Spot's Drugmaker, Zoetis, Digs Up A Breakout On Its Second-Quarter Beat

Zoetis trimmed its sales outlook Tuesday, but ZTS stock reversed a premarket dip and climbed on the easy second-quarter beat.

Investors Business Daily

Drug Maker Zoetis Stock Scores Relative Strength Upgrade

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Stock Market Holds Gains As Dow Keeps Run Going; Airline Stock Flashes Sell Signal

The Dow Jones notches a gain for the 12th day in a row. But airline stocks had a bumpy ride.

Investors Business Daily

Zoetis's Wetteny Joseph—one of the few Black CFOs in the Fortune 500—began his journey to finance chief in Haiti

Joseph shares his personal journey, discusses why representation matters, and explains what specific steps landed him in the C-suite.

Fortune

Spot's Drugmaker Claws Back Into The Green Despite Slowing Pet Sales

Animal health behemoth Zoetis posted an unusual first quarter, an analyst said Thursday after ZTS stock clawed back from a premarket dive.

Investors Business Daily

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens

A Relative Strength Rating upgrade for Zoetis stock shows improving technical performance. Will it continue?

Investors Business Daily

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73

A Relative Strength Rating upgrade for Zoetis shows improving technical performance. Will it continue?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Zoetis Stock Shows Rising Relative Strength Upgrades

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Zoetis Fetches A Quarterly Beat And Shares Surge To A Six-Month High

Animal health giant Zoetis beat fourth-quarter sales expectations Tuesday and issued a strong 2023 sales outlook, leading ZTS stock to pop.

Investors Business Daily

Mutual Funds Are Investing In 'Survivors' For 2023

Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.

Fortune

Top executives explain how they achieve ESG goals amid backlash

How should companies reframe ESG initiatives amid controversy? These executives offer their strategies.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

I asked the world’s top CEOs if they’re taking diversity seriously. Here’s why their answers could change your life

Corporate culture has entered the fourth phase in its history: the integration of purpose and profit, writes Robert Reiss.

Investors Business Daily

Zoetis Stock Yelps As Animal-Health Giant Hacks $200 Million-Plus Off Its Outlook

Zoetis trimmed its 2022 outlook on Thursday after the animal-health company missed third-quarter forecasts. ZTS stock tumbled.

Investors Business Daily

Fluffy's Drugmaker Trims 2022 Outlook As Livestock Sales Continue To Dive

Fluffy's drugmaker Zoetis offered a mixed second-quarter report Thursday, pushing ZTS stock to sink in early action.

Benzinga

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.08% on an annualized basis producing an average annual return of 22.15%. Currently, Zoetis has a market capitalization of $79.88 billion.

The Hindu

Explained | Ancovax - India’s first COVID-19 vaccine for animals

The Centre has launched a COVID-19 vaccine for animals such as dogs, lions, leopards, mice and rabbits.

Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 11.89% on an annualized basis producing an average annual return of 20.56%. Currently, Zoetis has a market capitalization of $75.58 billion.

Benzinga

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 21.83%. Currently, Zoetis has a market capitalization of $79.47 billion.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.